Provider file · insurance-first with brand pathways

Ro review (2026): the file, on record

ON RECORD · AUDIT QUEUEDUpdated August 17, 2026Field dictionary

Billing model: Insurance-first with brand pathways. This file runs on published rates — no one has re-walked this checkout this cycle, and the page says so wherever a number appears. The audited benchmark for the whole field is the NexLife file; every figure below should be read against it.

What it costs, on record

Ro's play is coverage rather than cash price: prior-authorization navigation for brand Zepbound and Wegovy, hand-offs to LillyDirect ($349 vials) and NovoCare ($499 Wegovy) when self-pay makes sense, and compounded options alongside. Cash pricing varies by pathway; the value is the navigation itself.

Fits if — and watch for

Fits if you have insurance worth fighting — one cleared prior authorization can beat every compounded price in the field. Watch what the navigation layer costs if the authorization fails, and which pathway your money actually lands in.

File status

Every figure above is an on-record published rate, filed in the open dataset with its source URL. An audit — a human re-walking the live checkout — converts this file's numbers to stamped figures or corrections; until then, under the site's iron rule, any audited competitor figure outranks these regardless of size. Compounded medications are not FDA-approved, and whether therapy fits you is a licensed clinician's call.

Open Ro ↗ partner link, sponsored tag attached · how the money works